VOLITIONRX LTD

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

VNRX$0.18-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Three Months Ended June 30, · Six Months Ended June 30,
	2026$		2025$		2026$	2025$
Revenues
Services		-		161,778		58,949	277,254
Product		398,657		244,910		1,324,784	375,819
Total Revenues		398,657		406,688		1,383,733	653,073
Operating Expenses
Research and development		1,800,656		2,720,207		4,652,907	5,327,321
General and administrative		2,205,471		2,940,754		4,858,283	5,184,116
Sales and marketing		548,513		1,043,534		1,400,214	1,960,833
Total Operating Expenses		4,554,640		6,704,495		10,911,404	12,472,270
Operating Loss		(4,155,983)		(6,297,807)		(9,527,671)	(11,819,197)
Other Income (Expenses)
Grant income (loss)		(45,914)		75,991		74,617	197,227
Gain on disposal of fixed assets		341		330		2,101	330
Interest income		163		160		179	318
Interest expense		(740,388)		(123,356)		(866,230)	(220,025)
Amortization of debt discount		(405,068)		(325,305)		(855,202)	(325,305)
Gain (loss) on change in fair value of derivative liability		(1,374,076)		418,681		(1,277,758)	418,681
Gain (loss) on change in fair value of warrant liability		1,162		(62,764)		14,578	(42,726)
Loss on extinguishment of debt		(595,500)		-		(1,583,434)	-
Total Other Income (Expenses)		(3,159,280)		(16,263)		(4,491,149)	28,500
Net Loss		(7,315,263)		(6,314,070)		(14,018,820)	(11,790,697)
Net Loss Attributable to Non-Controlling Interest		(10,784)		29,992		27,999	82,860
Net Loss Attributable to VolitionRx Limited Stockholders		(7,326,047)		(6,284,078)		(13,990,821)	(11,707,837)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments		72,313		(575,996)		206,620	(829,925)
Net Comprehensive Loss		(7,242,950)		(6,890,066)		(13,812,200)	(12,620,622)
Net Loss Attributable to VolitionRx Limited Stockholders		(7,326,047)		(6,284,078)		(13,990,821)	(11,707,837)
Deemed dividend - down round provision in warrants		(460,100)		-		(460,100)	-
Net Loss Attributable to Common Stockholders		(7,786,147)		(6,890,066)		(14,450,921)	(12,620,622)
Net Loss Per Share – Basic and Diluted Attributable to VolitionRx Limited		(0.85)		(1.22)		(1.80)	(2.35)
Weighted Average Shares Outstanding
– Basic and Diluted		9,154,815		5,132,705		8,018,292	4,980,599

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.